← Back to Search

Virus Therapy

Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1 (FORTRESS Trial)

Phase 2
Waitlist Available
Research Sponsored by Virios Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 week

Summary

This trial is testing a new medication called IMC-1 to see if it can help people with fibromyalgia feel better. Fibromyalgia causes widespread pain and fatigue, and current treatments may not work well for everyone. IMC-1 might reduce symptoms by targeting pain pathways in the body.

Eligible Conditions
  • Musculoskeletal Disease
  • Fibromyalgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Pain Score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IMC-1 Oral TabletExperimental Treatment1 Intervention
2X IMC-1 Tablet taken orally, each morning and evening.
Group II: PlaceboPlacebo Group1 Intervention
2X Placebo Tablet taken orally, each morning and evening.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMC-1
2021
Completed Phase 2
~570

Find a Location

Who is running the clinical trial?

Virios Therapeutics, Inc.Lead Sponsor
~94 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top